Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.

@article{Nitti2016DurableEA,
  title={Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.},
  author={Victor W. Nitti and David A Ginsberg and Karl-Dietrich Sievert and David Sussman and Sidney B. Radomski and Peter E. Sand and Dirk J M K de Ridder and Brenda Jenkins and Andrew Magyar and Christopher R. Chapple},
  journal={The Journal of urology},
  year={2016},
  volume={196 3},
  pages={
          791-800
        }
}
PURPOSE These are the final results of the prospective, multicenter, long-term (3.5-year) study of the efficacy/safety of onabotulinumtoxinA for overactive bladder syndrome. MATERIALS AND METHODS Patients who completed either of 2, 24-week phase 3 trials could enter a 3-year extension and continue treatment with onabotulinumtoxinA 100 U as needed to control overactive bladder symptoms. Data were analyzed by the treatment(s) received (up to 6) and in discrete subgroups that received 1, 2, 3, 4… CONTINUE READING